Madan Jagasia, Obsidian Therapeutics CEO

Ob­sid­i­an Ther­a­peu­tics rakes in $160M for sol­id tu­mor cell ther­a­py pro­gram

Ob­sid­i­an Ther­a­peu­tics an­nounced Wednes­day that it raised $160.5 mil­lion to push its tu­mor-in­fil­trat­ing lym­pho­cyte (TIL) pro­gram fur­ther in clin­i­cal tri­als.

The Se­ries C raise comes af­ter Ob­sid­i­an re­port­ed ini­tial da­ta from six pa­tients with ad­vanced melanoma who re­ceived its tu­mor-in­fil­trat­ing lym­pho­cyte cell ther­a­py. With the new $160.5 mil­lion, Ob­sid­i­an plans to push its TIL ther­a­py, OBX-115, for­ward in mul­ti­cen­ter stud­ies in both melanoma and non-small cell lung can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.